# Takeda: Phase 3 study completed, 354 enrolled (Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC))

**Score:** 100/100

| Field | Value |
|---|---|
| Sponsor | Takeda |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
| NCT ID | NCT04129502 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
| Intervention types | drug |
| Target enrollment | 354 |
| Site countries | United States, Australia, Austria, Belgium, Canada, China, France, Germany, Greece, Hong Kong, Israel, Italy |
| Posted | 2019-10-16 |
| Planned start | 2020-01-10 |
| Event | Completed |
| Event date | 2026-09-22 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 354 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT04129502). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.